News

For Release: October 2018 Development of therapies for human disease remains dependent on well-characterized and validated model systems.  Slow growing histologically benign tumors such as neurofibromas are challenging to grow in typical culture conditions.  As […]

For Release: October 2018 Neurofibromas are tumors of the nerve that are found most commonly in people with neurofibromatosis type I (NF1). NF1 is a neurogenetic disease with an estimated prevalence of 1/2500-1/3000.  A type […]

For Release: October 2018 Development of therapies for human disease remains dependent on well-characterized and validated model systems for pre-clinical therapeutic testing. Most in vitro drug testing is performed on cells growing in two dimensions […]

Author: Cathy Gara. July 2018–The Neurofibromatosis Therapeutic Acceleration Program (NTAP) at the Johns Hopkins University School of Medicine is proud to announce that Dr. Shruti Garg, of the University of Manchester, and Dr. Ina Ly, […]

The FY18 Neurofibromatosis Research Program (NFRP) is accepting applications for research projects. Applications to the Fiscal Year 2018 (FY18) Neurofibromatosis Research Program (NFRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development […]

July 10, 2018: One of the hallmarks of the complex syndrome Neurofibromatosis type 1 (NF1) are cutaneous neurofibromas (cNF).  cNF are tumors involving the skin that affect up to 99 percent of adults with NF1.  […]

New Research Tools Available in the Search for Therapies for Neurofibromatosis Type 1 Plexiform Neurofibromas By Cathy Gara | For Release: June 15, 2018 Plexiform neurofibromas affect up to 50 percent of people with neurofibromatosis […]

The Neurofibromatosis Therapeutic Acceleration Program (NTAP) at The Johns Hopkins School of Medicine is proud to announce that Dr. Angela Hirbe (Washington University) and Dr. Ping Chi (Memorial Sloan Kettering Cancer Center) have been selected […]

Bethesda, MD (December 28, 2016) NCI Press Release: In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the […]

Baltimore, MD (January 3, 2017)  Ashley Cannon, Ph.D., M.S., has been named the 2016 winner of the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research, sponsored by the Neurofibromatosis Therapeutic Acceleration Program […]

Baltimore, MD (October 1, 2014)  Neurofibromatosis Therapeutic Acceleration Program (NTAP) today announced that they have been selected as an Innovator Presenter at the 6th Annual Partnering for Cures meeting to be held in New York, […]

Baltimore, MD (June 9, 2014)  Two early career physician-scientists, Peter de Blank and Matthew R. Steensma, have been named inaugural winners of the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research, sponsored […]